Tag Archive for: Cancer

STORM Therapeutics to Present Data on its First-in-Class METTL1 tRNA Methyltransferase Inhibitors at AACR Annual Meeting 2024

/in

Late breaking presentation on STORM’s METTL1 inhibitors, for the treatment of cancer, on 8 April 2024 26 March 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announced that Alexandra Sapetschnig, Group Leader at STORM, […]

Read more

Novo Holdings Joins €30M Series A Financing for Asgard Therapeutics, Leader In In Vivo Cell Reprogramming To Treat Cancer

/in

Financing to advance first platform designed to reprogram cancer cells into immune cells as pan-tumoral cancer treatment Novo Holdings participation follows earlier investment and incubation through seed phase Financing co-led by RV Invest and Johnson & Johnson Innovation, joined by existing investors Boehringer Ingelheim Venture Fund and Industrifonden COPENHAGEN – March 14th, 2024 – Novo Holdings, […]

Read more

Asgard Therapeutics announces €30 million Series A financing to advance its first-in-class in vivo cell reprogramming platform for immuno-oncology

/in

Co-led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc. with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden Lead program is AT-108, a first-in-class, off-the-shelf intra-tumoral therapy that leads to personalized and potent anti-cancer immune responses Expanding R&D team to further develop AT-108 and broaden in vivo reprogramming […]

Read more

Optimum’s clients build momentum in March

/in

Optimum’s clients continued to gain momentum in March, starting things off on Monday with a substantial financing agreement for Heidelberg Pharma, with HealthCare Royalty for up to $115 million. On Wednesday, Heidelberg followed this with the announcement that it is to present first efficacy data from a Phase 1 clinical trial with ATAC candidate HDP-101. […]

Read more

US FDA grants Orphan Drug Designation for iOnctura’s first-in-class autotaxin cancer therapy

/in

Autotaxin inhibitor, IOA-289, recently received the proposed INN cambritaxestat Cambritaxestat is in the Phase I AION-02 trial in combination with chemotherapy in metastatic pancreatic cancer It is the first autotaxin inhibitor to be investigated in cancer patients Amsterdam, The Netherlands and Geneva, Switzerland, 7 March 2024 – iOnctura, a pioneering, clinical-stage biotechnology company developing transformative cancer […]

Read more